Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 1,902 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

NCT07661108
Conditions
Healthy
Interventions
MK-8527, Probenecid, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Onychomycosis
Interventions
Albaconozole, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
30% Nitrous oxide, 0.4% Sevoflurane, 0.2% sevoflurane, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intranasal Delivery of Testosterone and Its Effect on Doping Markers

NCT02611154
Conditions
Abuse of Anabolic Steroids
Interventions
Testosterone
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Not listed No phase listed Observational

Vascular Cardiotoxicity of Ponatinib

NCT03930394
Conditions
Cardiotoxicity
Interventions
Contrast ultrasound perfusion imaging
Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Healthy Volunteers
Interventions
Itraconazole, Rifampin, Golcadomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Lenexa, Kansas
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs

NCT00831129
Conditions
Pre-diabetes
Interventions
Rosiglitazone, Placebo Rosiglitazone, Simvastatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lumbar Degenerative Disease
Interventions
Abaloparatide
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
37
States / cities
Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more
Conditions
RSV Infection
Interventions
EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Not applicable Interventional

Centralized Reminder Recall - Flu RCT2

NCT03294473
Conditions
Influenza, Human, Orthomyxoviridae Infections, RNA Virus Infections, Virus Disease, Respiratory Tract Infections, Respiratory Tract Disease, Vaccines, Physiological Effects of Drugs
Interventions
R/R - Autodialers, R/R - Texting, R/R - mailed postcard
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months to 17 Years
Enrollment
70,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473
Conditions
Heroin Dependence
Interventions
Intranasal challenge drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
vepdegestrant, esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Lexapro Drug Interaction Study

NCT00361790
Conditions
Healthy
Interventions
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lenexa, Kansas
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

NCT03610282
Conditions
Anesthesia
Interventions
IV Methylphenidate, Propofol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclosporine, irinotecan hydrochloride, phenobarbital
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Healthy Volunteer
Interventions
Ozanimod, Gemfibrozil, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 2 Interventional Results available

Neoadjuvant Pazopanib in Renal Cell Carcinoma

NCT01361113
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial Comparison of Ototoxicity Monitoring Programs

NCT02099786
Conditions
Cisplatin Ototoxicity, Hearing Loss
Interventions
COMP-VA, Standard of care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of NSAIDs on Bone Metabolism Following Exercise

NCT05512013
Conditions
Bone Resorption, Stress Fracture, Bone Injury
Interventions
Ibuprofen 800 mg, Celecoxib 200mg, Flurbiprofen 100 mg, Placebo
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 42 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Conditions
Obesity, Overweight
Interventions
LY3437943, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Scottsdale, Arizona • Anaheim, California • Fresno, California + 21 more
Completed Not applicable Interventional Results available

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

NCT01490060
Conditions
Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
Interventions
Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Healthy
Interventions
ARV-471, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut